Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver.
Balzer
T
T
Schering AG, Berlin, Germany.
Carter
E C
EC
Shamsi
K
K
Niendorf
H P
HP
D018248:Adenoma, Liver Cell / Q000175:diagnosis; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis; D018281:Cholangiocarcinoma / Q000175:diagnosis; D003287:Contrast Media; D003911:Dextrans; D004305:Dose-Response Relationship, Drug; D052203:Ferrosoferric Oxide; D006391:Hemangioma / Q000175:diagnosis; D006801:Humans; D007501:Iron; D008107:Liver Diseases / Q000175:diagnosis*; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary; D008223:Lymphoma / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D010087:Oxides; D012680:Sensitivity and Specificity
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide